Advances and Challenges in Trials of Local Therapy for Patients With Oligometastatic or Oligoprogressive Disease

The oligometastatic paradigm and the role of radiotherapy

(2023) Killian Nugent et al.   CLINICAL MEDICINE

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

(2023) Stephanie G C Kroeze et al.   LANCET ONCOLOGY

Why Diverse Clinical Trial Participation Matters

(2023) Aaron L. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

(2023) Chad Tang et al.   JAMA Oncology

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC

(2022) Xiao-Shan Wang et al.   JNCI-Journal of the National Cancer Institute

Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives

(2022) Rémy Kinj et al.   Cancers

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations

(2022) Antonio Rossi et al.   Cancers

Progression-free survival: it is time for a new name

(2022) Bishal Gyawali et al.   LANCET ONCOLOGY

Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.

(2022) Rachel Woodford et al.   JOURNAL OF CLINICAL ONCOLOGY

NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).

(2022) Steven J. Chmura et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer

(2022) Robert Olson et al.   JAMA Oncology

Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy

(2022) Alexander Fabian et al.   JAMA Network Open

Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers

(2022) C.J. Tsai et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Imaging and its Impact on Defining the Oligometastatic State

(2021) Ali Pirasteh et al.   SEMINARS IN RADIATION ONCOLOGY

Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis

(2021) Xuguang Chen et al.   Cancer Medicine

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial

(2021) Shankar Siva et al.   EUROPEAN UROLOGY

Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy

(2021) Hanbo Chen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

(2021) L. Nicosia et al.   RADIOTHERAPY AND ONCOLOGY

Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment

(2021) Andrew G. Robinson et al.   Journal of Cancer Policy

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.

(2020) Piet Ost et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

(2020) Matthias Guckenberger et al.   LANCET ONCOLOGY

International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer

(2020) Morten Aa. Petersen et al.   QUALITY OF LIFE RESEARCH

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

(2020) Robert Olson et al.   BMC CANCER

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI

(2020) Oscar S.H. Chan et al.   LUNG CANCER

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

(2020) Ryan Phillips et al.   JAMA Oncology

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

(2020) Yolande Lievens et al.   RADIOTHERAPY AND ONCOLOGY

Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases—A Phase 2 Randomized Controlled Trial Within a Prospective Cohort

(2020) Bart J. Pielkenrood et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Predictive factors for response and survival in a cohort of oligometastatic patients treated with Stereotactic Body Radiation Therapy

(2019) Davide Franceschini et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

(2019) Daniel R. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

(2019) David A Palma et al.   LANCET

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

(2019) Joshua M. Bauml et al.   JAMA Oncology

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

(2019) David A. Palma et al.   BMC CANCER

Definition of synchronous oligo-metastatic non-small cell lung cancer – a consensus report

(2019) Anne-Marie C. Dingemans et al.   Journal of Thoracic Oncology

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer

(2018) Puneeth Iyengar et al.   JAMA Oncology

Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement

(2018) Karen M. Winkfield et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy

(2018) Ciro Franzese et al.   RADIOTHERAPY AND ONCOLOGY

Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937

(2017) Elizabeth M. Gore et al.   Journal of Thoracic Oncology

Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? A simulation study to evaluate the feasibility of the Cluster cmRCT design

(2016) Alexander Pate et al.   BMC Medical Research Methodology

Decision Aids Can Support Cancer Clinical Trials Decisions: Results of a Randomized Trial

(2016) M. C. Politi et al.   ONCOLOGIST

The Strength of Association Between Surrogate End Points and Survival in Oncology

(2015) Vinay Prasad et al.   JAMA Internal Medicine

Implementing patient-reported outcome measures in palliative care clinical practice: A systematic review of facilitators and barriers

(2013) Bárbara Antunes et al.   PALLIATIVE MEDICINE

Oligometastases revisited

(2011) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables

(2008) James R. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY